Nirsevimab: Alleviating the burden of RSV morbidity in young children
Journal of Paediatrics and Child Health · 2024-10 · 60 (10) · 489-498
DOI: 10.1111/jpc.16643 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Paediatrics and Child Health, online erschienen am 16.08.2024. Verfasst von Marcus Wing Choy Loe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke-NUS Medicine School, Singapore. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTIs) and hospital admissions in early childhood. Recent advancements in novel preventive therapies, including extended half‐life monoclonal antibodies and antenatal vaccination, have afforded new opportunities to significantly reduce the burden of this infection. Nirsevimab is a novel monoclonal antibody that provides sustained protection against RSV for at least 5 months among newborns and young children. It has received regulatory approval in numerous countries and is being implemented across various settings. Two pivotal Phase 3 trials (MELODY, HARMONIE) demonstrated significant reductions in RSV‐associated LRTI hospitalisations following nirsevimab administration, with treatment efficacy of 62.1% and 83.2%. Emerging real‐world data from early adopters of nirsevimab corroborates these findings. Studies from Spain, Luxembourg, France and the USA report effectiveness rates between 82% and 90% in preventing RSV‐associated hospitalisations among infants entering their first RSV season. Current implementation strategies for nirsevimab have primarily focused on seasonal administration for all infants, aligned to local RSV seasons, and often include catch‐up doses for those born before the season begins. Available cost‐effectiveness analyses indicate that while nirsevimab offers significant potential public health benefits, its adoption must carefully consider economic factors such as treatment costs, implementation strategies tailored to local viral epidemiology, and logistics for vaccine delivery. Overall, nirsevimab presents a promising opportunity to alleviate the burden of severe RSV infections in young children. However, ongoing surveillance and refinements in implementation strategies are crucial to optimise its impact and ensure sustainability across diverse health‐care settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke-NUS Medicine School, Singapore.
- Department of Neonatology, KK Women's & Children's Hospital, Singapore.
- School of Women's and Children's Health, University of New South Wales, Randwick, New South Wales, Australia.
- Centre for Economic Impacts of Genomic Medicine, Macquarie University, Sydney, New South Wales, Australia.
- Centre for Social Research in Health, University of New South Wales, Sydney, Australia.
- National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.
ORCID-Profile: Evelyn Lee, Phoebe Cm Williams, Kee Thai Yeo
Zitieren
APA
Loe, M. W. C., Soenong, H., Lee, E., Li-Kim-Moy, J., Williams, P. C., & Yeo, K. T. (2024). Nirsevimab: Alleviating the burden of RSV morbidity in young children. Journal of Paediatrics and Child Health, 60(10), 489-498. https://doi.org/10.1111/jpc.16643
Vancouver
Loe MWC, Soenong H, Lee E, Li-Kim-Moy J, Williams PC, Yeo KT. Nirsevimab: Alleviating the burden of RSV morbidity in young children. Journal of Paediatrics and Child Health. 2024;60(10):489-498. doi:10.1111/jpc.16643
BibTeX
@article{Loe2024,
author = {Loe, Marcus Wing Choy and Soenong, Helen and Lee, Evelyn and Li-Kim-Moy, Jean and Williams, Phoebe Cm and Yeo, Kee Thai},
title = {Nirsevimab: Alleviating the burden of RSV morbidity in young children},
journal = {Journal of Paediatrics and Child Health},
year = {2024},
volume = {60},
number = {10},
pages = {489--498},
doi = {10.1111/jpc.16643}
}
EUVIMED